David Riley, M.D.                                Integrative Medicine

Bibliography of Iscador References

Mistletoe has been reviewed by experts at the National Institutes of Health as an adjunctive complementary treatment for cancer.

  1. A review of mistletoe use in cancer was completed by the University of Texas Center for Alternative Medicine Research in Cancer in 1997 by Mary Ann Richardson, PhD. 

Currently she is a program officer at the NIH - National Center for Complementary and Alternative Medicine in Bethesda, Maryland.

  1. Dr. Jeffery White, Director of the Office of Cancer Complementary and Alternative Medicine at the National Cancer Institute, in 1998 provided an overview of mistletoe to the Cancer Advisory Panel (CAP) of the NIH Office of Alternative Medicine. Dr. White noted that the scientific literature suggests that mistletoe may have anti-tumor effects and may enhance survival.

Mistletoe References

  1. Addington-Hall JM, MacDonald LD, Anderson HR: Can the Spitzer Quality of Life Index help to reduce prognostic uncertainty in terminal care? Br J Cancer Oct;62(4):695-9, 1990.
  2. Awwad S, Cull A, Gregor A: Long-term survival in adult hemispheric glioma: prognostic factors and quality of outcome. Clin Oncol (R Coll Radiol) Nov;2(6):343-6, 1990.
  3. Bauman GS, Gaspar LE, Fisher BJ, Halperin EC, Macdonald DR, Cairncross JG: A prospective study of short-course radiotherapy in poor prognosis glioblastoma multiforme. Int J Radiat Oncol Biol Phys 29:835-839, 1994.
  4. Beuth J, Ko HL, Gabius HJ, Burrichter H, Oette K, Pulverer G. Behavior of lymphocyte subsets and expression of activation markers in response to immunotherapy with galactoside specific lectin from mistletoe in breast cancer patients. Clin Investig 70, 658-61 (1992).
  5. Beuth J, Ko HL, Gabius HJ, Pulverer G. Influence of treatment with the immunomodulatory effective dose of the b-galactoside specific lectin from mistletoe on tumor colonization in BALB/c-mice for two experimental model systems. In Vivo 5 (1), 29-32 (1991).
  6. Beyersdorff D., Irmey G. Die kostenerstattung biologischer heilmittel bei krebserkrankungen in der arztlichen praxis. Erfahrungsheilkunde. 1996:82-90.
  7. Böhringer B. Personal communication to principal investigator. March 29, 2001.
  8. Boie 1980.
  9. Boie D, Gutsch J. Helixor in cancer of colon and rectum. Schriftenreihe Krebsgeschehen. 1980;23:65-76.
  10. Bruera E, Neumann CM. Management of specific symptom complexes in patients receiving palliative care. CMAJ 1998;158(13):1717-26.
  11. Buhl K, P Schlag, C Herfarth: Quality of life and functional results following different types of resection for gastric carcinoma. Eur J Surg Oncol 16:404-409, 1990.
  12. Burger AM, Mengs U, Schüler JB, Zinke H, Lentzen H and Fiebig HH. Recombinant mistletoe lectin (ML) is a potent inhibitor of tumor cell growth in vitro and in vivo. Proceedings of the American Association for Cancer Research 40, 399-399 (1999).
  13. Büssing A. Mistletoe. The Genus Viscum. Harwood Academic Publishers, Amsterdam, 2001.
  14. Büssing A. Azhari A, Ostendorp H, Lehnert A, Schweizer K. Viscum album L. estracts reduce sister chromatid exchanges in cultured peripheral blood mononuclear cells. Eur J Cancer. 1994;30A:1836-1841.
  15. Büssing A, Regnery A, SChweizer K. Effects of Viscum album L. on cyclophosphamide-treated peripheral blood mononuclear cells in vitro: Sister chromatid exchanges and activation/proliferation marker expression. Cancer Letters. 1995;94:199-205.
  16. Büssing A, Richardson MA. Life protecting and deadly—a survey of basic research on the biological properties of mistletoe (Viscum album L.)
  17. Bussing A, Suzart K, Bergmann J, Pfuller U, Schietzel M, Schweizer K. Induciton of apoptosis in human lymphocytes treated with Viscum Album L. is mediated by the mistletoe lectins. Cancer Letters 99, 59-72 (1996)
  18. Bussing A. Mistletoe: a story with an open end. Anti-Cancer Drugs (Suppl). 1997;8:S1-S2.
  19. Clark WC: Pain sensitivity and the report of pain. Anesthesiology 40:272-275, 1977.
  20. Cleeland CS: Measurement and prevalence of pain in cancer. Semin Oncol Nurs 1:87-96, 1985.
  21. Daut R, Cleeland C, Flanery R: Development of the Wisconsin Brief Pain questionnaire to assess pain in cancer and other diseases. Pain 17:197-210, 1983.
  22. Dold U, et al. Krebszusatztherapie beim fortgeschrittenen nicht-kleinzelligen Bronchialkarzinom, pp. 1-144, Georg Thieme Verlag, Stuttgart-New York 1991.
  23. Endo Y, Tsuguri K, Franz H: The site of action of the A chain of mistletoe lectin on eukaryotic ribosomes. FEBS Letters 231 (2) 378-380 (1988).
  24. Elsasser-Beile U; Voss M; Schuhle R; Wetterauer U. Biological effects of natural and recombinant mistletoe lectin and an aqueous mistletoe extract on human monocytes and lymphocytes in vitro. J Clin Lab Anal 2000;14(6):255-9    
  25. Ferrell BR, Rhiner M, Cohen, M, Grant, M.  Pain as a metaphor for illness. Part I: impact of cancer pain on family caregivers.  Onc Nurs Forum. 1991, 18 (8);1303-1309.
  26. Franz H, Friemel H, Buchwald S, Palntikow A, Kopp J, Korner IJ. The A chain of lectin I from European mistletoe (Viscum album) induces interleukin-I and interleukin-II in human mononuclear cells. In: Lectins Biol Biochem, Vol 7, pp 247-250. Eds. Kocourek J, Freed DLJ. Sigma Chemical Company, St. Louis, Missouri, USA. 1990.
  27. Friess H, Beger HG, Kunz N, Schilling M, Buchler MW. Treatment of advanced pancreatic cancer with mistletoe: results of a pilot trial. Anticancer Res 16(2):915-20, 1996.
  28. Gabius HJ, et al. The risk potential of alternative (herbal) medicine: tumor stimulation by mistletoe lectin present in proprietary extracts. [Abstract #1151]. Proceedings of the American Association for Cancer Research. 2001.
  29. Glaus A. Assessment of fatigue in cancer and non-cancer patients and in healthy individuals.  Support Care Cancer 1:305-315, 1993.
  30. Gorter RW, van Wely M, Reif M, Stoss M. Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Alt Ther Health Med 1999;5:37-48.
  31. Gray AM; Flatt PR. Insulin-secreting activity of the traditional antidiabetic plant Viscum album (mistletoe). J Endocrinol 1999 Mar;160(3):409-14.   
  32. Grossarth-Maticek R, Kiene H, Baumgartner SM, Vetter H. Viscum album (Iscador) in cancer treatment. A systemic epidemiology investigation: Prospective Non-randomized and Randomized matched-pair studies nested within a cohort study. Altern Ther Health Med. 2001;7(3).
  33. Hajto T, Hostanka K, Fornalski M, Kirsch A. Antitumorale aktivität des immunmodulatorisch wirkenden beta-galactosidspezifischen mistellektins bei der klinischen anwendung von mistelextrakten (Iscador). Dtsch Z Onkologie 1991;23:1-6.
  34. Hajto T, Hostanka K, Steinberg F, Gabius HJ: b-galactoside specific lectin from clinically applied mistletoe extract reduces tumor growth by augmentation of host defense system. Blut 61, 164 (1990a).
  35. Hajto T, Hostanska K, Frei K, Rordorf HJ, Gabius HJ: Increased secretion of tumor necrosis factor, interleukin 1, and interleukin 6 by human mononuclear cells exposed to b-galactoside-specific lectin from clinically applied mistletoe extract. Cancer Res 50, 3322-6 (1990b).
  36. Hajto T. Immunomodulatory effects of Iscador: A Viscum album preparation. Oncolog. 1986;43(suppl 1)52-65.
  37. Hajto T; Hostanska K; Saller. Mistletoe therapy from the pharmacologic perspective. Forsch Komplementarmed 1999 Aug;6(4):186-94 .  
  38. Hamprecht K, Handgretinger R, Voetsch W,Anderer FA. Mediation of human NK-activity by components in extracts of Viscum album. Int.J.Immunopharmac. 9, 199-209 (1987).
  39. Hauser SP. Mistel: Wunderkraut oder medikament? Klinische anwendung von mistlepräparaten in der onkologie. Therapiewoche. 1993a;43:76-81.
  40. Hauser SP. Unproven methods in cancer treatment. Curr Opinion Oncol 1993b;(5):646-54.
  41. Heiny BM, Albrecht V. Komplementäre Therapie mit Mistellektin-1-normiertem Extrakt. Lebensqualitätsstabilisierung beim fortgeschrittenen kolorektalen Karzinom—Fakt oder Fiktion? Die Medizinische Welt 48, 419-423 (1997).
  42. Heiny BM, Beuth J. Mistletoe extract standardized for the galactoside-specific lectin (ML-I) induces b-endorphin release and immunopotentiation in breast cancer patients. Anticancer Res. 1994;14:1339-1342.
  43. Heiny BM. Additive Therapie mit standardisiertem Mistelextrakt reduziert die Leukopenie und verbessert die Lebensqualität von Patientinnen mit fortgeschrittenem Mammakarzinom unter palliativer Chemotherapie (VEC-Schema). Krebsmedizin 12, 1-14 (1991)
  44. Hostanka K, Hajto T, Spagnoli GC, Fischer J, Lentzen H, Herrmann R. A plant lectin derived from Viscum album induces cytokine gene expression and protein production in cultures of human peripheral blood mononuclear cells. Natural Immunity 14, 295-304 (1995).
  45. Ingham, JM, Foley, DM. Pain and the barriers to its relief at the end of life: a lesson for improving end of life health care. Hosp J. 1998; 89-100.
  46. Jung ML, Frantz M, Ribéreau-Gayon G, Anton R. Die Mistellektine: Einfluss von Serum und Kohlenhydraten auf die Zytotoxizität und Stimuliering der Zytokinproduktion. In: Grundlagen der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung; (Eds. R. Scheer, H. Becker and P.A. Berg) pp. 302-314, in: Edition Forschung.(Karl und Veronica Carstens-Stiftung), Hippokrates Verlag GmbH, Stuttgart 1996.
  47. Jurin M, Zarkovic N, Borovic S,Kissel D. Immunomodulation by the Viscum album L. preparation Isorel and its antitumorous effects. In: Grundlagen der Misteltherapie. Aktueller Stand der Forschung und klinische Anwendung; (Eds. R. Scheer, H. Becker and P.A. Berg) pp. 315-324,  in: Edition Forschung.(Karl und Veronica Carstens-Stiftung), Hippokrates Verlag GmbH, Stuttgart 1996.
  48. Jurin M, Zarkovic N, Hrzenjak M, Ilic Z. Antitumorous and immunomodulatory effects of the Viscum album L. preparation Isorel. Oncology 50, 393-398 (1993).
  49. Kaegi E. Unconventional therapies in cancer: 3. Iscador. CMAJ 1998;158:1157-1159.
  50. Khwaja TA, Dias CB, Pentecost S. Recent studies on the anticancer activities of Mistletoe (Viscum album) and its alcaloids. Oncology 43, 42-50 (1986).
  51. Kiene H. Klinische Studien zur Misteltherapie karzinomatöser Erkankungen. Eine Übersicht. therapeutikon 1989;3(6):347-53.
  52. Kleijnen J, Knipschild P. Mistletoe treatment for cancer: Review of controlled trials in humans. Phytomedicine 1:255-260; 1994.
  53. Klein-Franke A, Anderer FA. IL-12-mediated activation of MHC-unrestricted cytotoxicity of human PBMC subpopulations: Synergistic action of a plant rhamnogalacturonan. Anticancer Research 2511-2516 (1995).
  54. Klett CY, Anderer FA. Activation of natural killer cell cytotoxicity of human blood monocytes by a low molecular weight component from viscum album extract. Arzneim-Forsch/Drug Res 39 (II), 1-20 (1989).
  55. Koch FE. Experimentelle Untersuchungen über entzundungs und nekroseerzeugende Wirkung von Viscum album. Z exp Med 103. 740-9 (1938).
  56. Kovacs E, Hajto T, Hostanska. Improvement of DNA repair in lymphocytes of breast cancer patients treated with Viscum album extract (Iscador). Europ J Cancer. 1991;27:1672-1676.
  57. Kubasova T, Pfuller U, Koteles GJ, Csollak M, Eifler R. Comparative studies on some cellular and immunological effects of mistletoe isolectin in vitro. In: Lectins: Biology, Biochemistry, Vol 11, pp 240-44. Eds: Van Driessche E, Rouge P, Beeckmans S, Bog-Hansen TC. Textop, Hellerup (Denmark) 1996.
  58. Kuehn, J. J., Löhmer, H., Sommer, H., Fornalski, M., and Kindermann, G. Prospectiv randomisierte Prüfung der Wirksamkeit und Verträglichkeit einer adjuvanten Misteltherapie (Iscador®) bei Nachbestrahlung nach Mammakarzinomoperation . 2000.
  59. Kunze E, Schulz H, Ahrens H, Gabius HJ. Lack of an antitumoral effect of immunomodulatory galactoside-specific mistletoe lectin on N-methyl-N-nitrosourea-induced urinary bladder carcinogenesis in rats. Exp.Toxic Pathol. 49, 167-180 (1997).
  60. Kunze E, Schulz H, and Gabius HJ. Inability of galactoside-specific mistletoe lectin to inhibit N-methyl-N-nitrosourea-induced tumor development in the urinary bladder of rats and to mediate a local cellular immune response after long-term administration. J.Cancer Res.Clin.Oncol. 124, 73-87 (1998).
  61. Kuttan G, Kuttan R, Immunological mechanism of action of the tumor reducing peptide from mistletoe extract (NSC 635089) cellular proliferation. Cancer Letters 123-130 (1992).
  62. Kuttan G, Kuttan R. Reduction of leukopenia in mice by Viscum album administration during radiation and chemotherapy. Tumori. 1993;79:74-76.
  63. Kuttan G, Vasudevan DM, Kuttan R. Isolation and identification of a tumor reducing component from mistletoe extract. Cancer Letters 307-314 (1988).
  64. Lange O, Scholz G, Gutsch J. Modulation of the subjective and objective toxicity of aggressive radiochemotherapy with Helixor. Unpublished Study.
  65. Lenartz D, Stoffel B, Menzel J, Beuth J. Immunoprotective activity of the galactoside-specific lectin from mistletoe after tumor destructive therapy in glioma patients. Anticancer Research. 1996;16:3799-802.
  66. Lukyanova EM, Chernyshov VP, Omelchenko LJ et al. Iscador treatment of immuno-compromised children after the Chernobyl accident: clinical and immunological investigations. Forschende Komplementärmed. 1994;1:58-70.
  67. Luther P et al. Official report. Forsch Inst Lungenkrankh DDR, Berlin, 1984
  68. Martindale¾The Complete Drug Reference. Volume 107. 2001.
  69. McNair D, Lorr M, Droppleman L.  Profile of mood states manual.  San Diego, CA: EdITS, 1992.
  70. Metzner G, Franz H, Kindt A, Fahlbusch B, Suss J. The in vitro activity of lectin I from mistletoe (MLI) and its isolated A and B chains on functions of macrophages and poly-morphonuclear cells. Immunobiology 169, 461-71 (1985).
  71. Metzner G, Franz H, Kindt A, Schumann I, Fahbusch B. Effects of lectin I from mistletoe (ML-I) and its isolated A and B chains on human mononuclear cells: mitogenic activity and lymphokine release. Pharmazie 42 (5), 337-40 (1988).
  72. Mueller EA, Anderer FA. A Viscum album oligosaccharide activating human natural cytotoxicity is an interferon gamma inducer. Cancer Immunol.Immunother. 221-227 (1990).
  73. Mueller EA, Anderer FA. Chemical specificity of effector cell/tumor cell bridging by a Viscum album rhamnogalacturonan enhancing cytotoxicity of human NK cells. Immunopharmacology 69-77 (1990).
  74. Nail LM, King KB. Fatigue.  Sem Oncol Nurs 3:257-262, 1987.
  75. Neuenschwander, H & Bruera, E. Asthenia. In: Doyle, D, Hanks, G.W.C. & MacDonald, N. eds. Oxford Textbook of Palliative Medicine. 2nd Ed. New York: Oxford University Press. 1998.573-581.
  76. Ovesen L, Allingstrup L, Hannibal J, Mortensen EL, Hansen OP: Effect of dietary counseling on food intake, body weight, response rate, survival, and quality of life in cancer patients undergoing chemotherapy: a prospective, randomized study. Ovesen L et al. JCO 11:2043-2049, 1993.
  77. Pae HO; Seo WG; Oh GS; Shin MK; Lee HS; Lee HS; Kim SB; Chung HT. Potentiation of tumor necrosis factor-alpha-induced apoptosis by mistletoe lectin. Immunopharmacol Immunotoxicol 2000 Nov;22(4):697-709    
  78. Pan CX, et al. Complementary and alternative medicine in the management of pain, dyspnea, and nausea and vomiting near the end of life: a systematic review. J Pain Symptom Manage 2000;20:374-387.
  79.  Park R; Kim M; So H; Jung B; Moon S; Chung S; Ko C; Kim B; Chung H. Biochem       Pharmacol 2000 Dec 1;60(11):1685-1691    
  80. Reynolds J (ed). Martindale Extra Pharmacopoeia. Pharmaceutical Press. 1996
  81. Ribéreau-Gayon G, Jung ML, Beck JP, and Anton R. Effects of serum proteins on the cytotoxic activity and antibody interaction of mistletoe lectins in cell culture. Planta Med. 59, A 673-A 674(1993).
  82. Schwabe U., Paffarath D. Arzneiverordnungsreport 1998. Heidelberg: Springer Verlag; 1998.
  83. Schwartz AL. Reliability and validity of the Schwartz Cancer Fatigue Scale. Oncol Nurs F, 1998.
  84. Serlin RC, Mendoza TR, Nakamura Y, Edwards KR, Cleeland CS: When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function. Pain 61:277-284, 1995.
  85. Spitzer WO, Dobson AJ, Hall J, Chesterman E, Levi J, Shepherd R, Battista RN, Catchlove BR: Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis 34(12):585-97, 1981.
  86. Stein G, Berg PA. Evaluation of the stimulatory activity of a fermented mistletoe lectin-I free mistletoe extract on T-helper cells and monocytes in healthy individuals in vitro. Drug Res 46 (6), 35-9 (1996).
  87. Stein GM, Schaller G, Pfüller U, Schietzel M, Büssing A. Thionins from Viscum album L: Influence of the viscotoxins on the activation of granulocytes. Anticancer Research 19, 1037-1042 (1999).
  88. Stirpe F, Legg RF, Onyon LJ, Ziska P, Franz H. Inhibition of protein synthesis by a toxic lectin from Viscum album L. (mistletoe). Biochem J 190, 843-5 (1980).
  89. Stumpf C; Rosenberger A; Rieger S; Troger W; Schietzel M. Mistletoe extracts in the therapy of malignant, hematological and lymphatic diseases--a monocentric, retrospective analysis over 16 years. Forsch Komplementarmed Klass Naturheilkd 2000 Jun;7(3):139-46.   
  90. SUPPORT Principle Investigators. A controlled trial to improve care for seriously ill hospitalized patients:The study to understand prognosis and preferences for outcomes and risks for treatment (SUPPORT).  Journal of the American Medical Association. 1995, 274: 1591-1598.
  91. Tamburini M, Filiberti A, Barbieri A, Zanoni F, Pizzocaro G, Barletta L, Ventafridda V: Psychological aspects of testis cancer therapy: a prospective study. J Urol Dec;142(6):1487-9, 1989.
  92. Wagner R. Treatment of Cancer with Iscar: 160 Frequently Asked Questions and Answers. Mercury Press, Spring Valley, NY, 2000, pp25-6.
  93. Walsh, D. Symptom control in advanced cancer.  American Society of Clinical Oncology. 1997: 295-302.
  94. Wolf P, Freudenberg N, Konitzer M,. Analgetische und stimmungsaufhellende wirkung bei malignom-patienten unter hochdosierter Viscum-album-infusiontherapie. Erfahrungsheilkunde 43 (5), 262-4, 1994.
  95. Zhu HG, Zollner TM, Klein-Franke A, Anderer FA. Activation of human monocyte/macrophage cytotoxicity by IL-2/IFNy is linked to increased expression of an antitumor receptor with specificity for acetylated mannose. Immunology Letters 38, 111-119 (1993).